To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Recruiting · NCT06378242 · Registry updated 2024-07-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 | High-risk Non-muscle Invasive Bladder Cancer | Recruiting | Phase 1 / Phase 2 | 2024-07-11 | NCT06378242 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| RemeGen Co., Ltd. | 36 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Changsha | China | 87 |
| Sun Yat-sen Memorial Hospital,SunYat-sen University | Guangzhou | China | 1 |
| The first affiliated hospital with nanjing medical universtity | Nanjing | China | 1 |
| Tianjin Medical University Second Hospital | Tianjin | China | 2 |
| Tongji Hospital | Wuhan | China | 25 |
| West China Hospital | Chengdu | China | 21 |